$MRK Cashflow Statement | Understand Stock

$MRK

$142.15 +$1.54 (1.1%) Live

$MRK Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statement of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash Flows from Operating Activities
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization
Depreciation
Intangible asset impairment charges
Income from investments in equity securities, net
Charge for the acquisition of Prometheus Biosciences, Inc.
Charge for the acquisition of Imago BioSciences, Inc.
Charges for certain research and development asset acquisitions
Deferred income taxes
Share-based compensation
Other
Net changes in assets and liabilities:
Accounts receivable
Inventories
Trade accounts payable
Accrued and other current liabilities
Income taxes payable
Noncurrent liabilities
Other
Net Cash Provided by Operating Activities
Cash Flows from Investing Activities
Purchase of Seagen Inc. common stock
Capital expenditures
Purchases of securities and other investments
Proceeds from sales of securities and other investments
Proceeds from sale of Seagen Inc. common stock
Acquisition of Verona Pharma plc, net of cash acquired
Acquisition of Eyebiotech Limited, net of cash acquired
Acquisition of Elanco Animal Health Incorporated aqua business
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired
Acquisition of MK-1045 from Curon Pharmaceutical
Acquisition of Prometheus Biosciences, Inc., net of cash acquired
Acquisition of Imago BioSciences Inc., net of cash acquired
Acquisition of Peloton Therapeutics, Inc., net of cash acquired
Other
Net Cash Used in Investing Activities

Cash Flows from Financing Activities
Net change in short-term borrowings
Payments on debt
Distribution from Organon & Co.
Proceeds from issuance of debt
Purchases of treasury stock
Dividends paid to stockholders
Proceeds from exercise of stock options
Other
Net Cash (Used in) Provided by Financing Activities of Continuing Operations
Net cash provided by operating activities
Net cash used in investing activities
Net cash used in financing activities
Net Cash Flows Provided by Discontinued Operations
Net Cash Used in Financing Activities
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $76, $68 and $79 of restricted cash at January 1, 2025, 2024 and 2023, respectively, included in Other current assets)
Less: Cash and cash equivalents related to discontinued operations
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $125, $76 and $68 of restricted cash at December 31, 2025, 2024 and 2023, respectively, included in Other current assets)

Comments